[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgqqx59uB4_R2RArWdJLVwzuEDSDCpkYTvR_TGnmSEIQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":85,"rows":92},"Ottawa Heart Institute Research Corporation",[4],180,false,59,30,85153,20,128,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Coronary Artery Disease",31,{"name":18,"count":19},"Atrial Fibrillation",19,{"name":21,"count":22},"Heart Failure",15,{"name":24,"count":25},"Acute Coronary Syndrome",10,{"name":27,"count":25},"Cardiovascular Diseases",{"name":29,"count":30},"Coronary Heart Disease",9,{"name":32,"count":33},"Smoking Cessation",8,{"name":35,"count":36},"Myocardial Infarction",5,[38,43,48,52,56,61,65,70,75,80],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07059377","Semaglutide for Smoking Cessation in Patients With Diabetes","2026-07","Semaglutide",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05267886","CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock","2026-12","Dobutamine",{"nctId":49,"briefTitle":50,"date":46,"intervention":51},"NCT03593759","Cardiac Sarcoidosis Randomized Trial","Prednisone or Prednisolone",{"nctId":53,"briefTitle":54,"date":46,"intervention":55},"NCT05427084","Canagliflozin Targeting Vascular Inflammation","Canagliflozin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06710080","Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia","2026-12-31","Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]",{"nctId":62,"briefTitle":63,"date":59,"intervention":64},"NCT05037799","Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease","Rb-82 Radioisotope",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04770012","AERIAL Trial: Antiplatelet Therapy in Heart Transplantation","2027-03","aspirin",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06832085","Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation","2027-04-30","Nicotine Replacement Therapy",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06281977","Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm","2027-05-08","Dexmedetomidine",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06174753","Dapagliflozin in STEMI","2027-06","Dapagliflozin 10mg Tab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,143,174,196,230,256,274,304,333,387,416,440,458,484,505,528,546,569,596,617,639,687,722,749,767,785,809,827,855,873,891,918,936,954,984,1008,1026,1050,1074,1099,1117,1141,1159,1181,1207,1233,1254,1272,1290,1316,1334,1357,1381,1406,1430,1453,1477,1503,1521,1547,1565,1590,1608,1631,1657,1675],{"intervention":94,"totalTrials":95,"cells":96},"Normal saline",3,{"EARLY_PHASE1":97,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":130,"NA":141},{"trials":98,"activeCount":106},[99],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT05634213","Feasibility of Transepicardial Atrial Injection","WITHDRAWN",[86],"2025-04-01","2023-03-01",0,[108],"Cardiac Surgery",[110],"normal saline",{"trials":112,"activeCount":106},[],{"trials":114,"activeCount":106},[],{"trials":116,"activeCount":129,"soonestReadout":78},[117],{"nctId":76,"briefTitle":77,"status":118,"phases":119,"primaryCompletion":78,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":128},"RECRUITING",[89],"2027-08-01","2024-05-08",192,[124,125,126,127],"Ventricular Tachycardia","Ventricular Arrhythmias","Ventricular Fibrillation","Recurrent Ventricular Tachycardia",[79,94],1,{"trials":131,"activeCount":129,"soonestReadout":46},[132],{"nctId":44,"briefTitle":45,"status":118,"phases":133,"primaryCompletion":46,"completion":46,"start":134,"enrollment":135,"conditions":136,"interventions":138},[90],"2022-03-05",346,[137],"Shock, Cardiogenic",[47,139,140],"Milrinone","Normal Saline",{"trials":142,"activeCount":106},[],{"intervention":47,"totalTrials":144,"cells":145},2,{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":172},{"trials":147,"activeCount":106},[],{"trials":149,"activeCount":106},[],{"trials":151,"activeCount":106},[],{"trials":153,"activeCount":106},[],{"trials":155,"activeCount":129,"soonestReadout":46},[156,160],{"nctId":44,"briefTitle":45,"status":118,"phases":157,"primaryCompletion":46,"completion":46,"start":134,"enrollment":135,"conditions":158,"interventions":159},[90],[137],[47,139,140],{"nctId":161,"briefTitle":162,"status":163,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":122,"conditions":167,"interventions":171},"NCT03207165","Milrinone Versus Dobutamine in Critically Ill Patients","COMPLETED",[90],"2020-06-12","2017-08-30",[168,169,24,170],"Low Cardiac Output Syndrome","Cardiogenic Shock","Pulmonary Edema",[139,47],{"trials":173,"activeCount":106},[],{"intervention":139,"totalTrials":144,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":194},{"trials":177,"activeCount":106},[],{"trials":179,"activeCount":106},[],{"trials":181,"activeCount":106},[],{"trials":183,"activeCount":106},[],{"trials":185,"activeCount":129,"soonestReadout":46},[186,190],{"nctId":44,"briefTitle":45,"status":118,"phases":187,"primaryCompletion":46,"completion":46,"start":134,"enrollment":135,"conditions":188,"interventions":189},[90],[137],[47,139,140],{"nctId":161,"briefTitle":162,"status":163,"phases":191,"primaryCompletion":165,"completion":165,"start":166,"enrollment":122,"conditions":192,"interventions":193},[90],[168,169,24,170],[139,47],{"trials":195,"activeCount":106},[],{"intervention":197,"totalTrials":144,"cells":198},"Varenicline",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":228},{"trials":200,"activeCount":106},[],{"trials":202,"activeCount":106},[],{"trials":204,"activeCount":106},[],{"trials":206,"activeCount":106},[],{"trials":208,"activeCount":129,"soonestReadout":73},[209,219],{"nctId":210,"briefTitle":211,"status":163,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},"NCT00959972","Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease",[90],"2010-11","2009-04",50,[29],[197,218],"Transdermal Nicotine Patch",{"nctId":71,"briefTitle":72,"status":118,"phases":220,"primaryCompletion":73,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":226},[90],"2027-10-30","2025-04-30",150,[225],"Tobacco",[74,227,197],"Cytisine",{"trials":229,"activeCount":106},[],{"intervention":231,"totalTrials":129,"cells":232},"Genotyping guided therapy for anti-platelet management",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":254},{"trials":234,"activeCount":106},[],{"trials":236,"activeCount":106},[],{"trials":238,"activeCount":106},[],{"trials":240,"activeCount":106},[],{"trials":242,"activeCount":129,"soonestReadout":248},[243],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT07602257","Investigating a Personalized Approach to Anti-Platelet Therapy","NOT_YET_RECRUITING",[90],"2029-12-28","2026-06-01",1760,[252],"High Risk Bleeding",[231],{"trials":255,"activeCount":106},[],{"intervention":74,"totalTrials":129,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":272},{"trials":259,"activeCount":106},[],{"trials":261,"activeCount":106},[],{"trials":263,"activeCount":106},[],{"trials":265,"activeCount":106},[],{"trials":267,"activeCount":129,"soonestReadout":73},[268],{"nctId":71,"briefTitle":72,"status":118,"phases":269,"primaryCompletion":73,"completion":221,"start":222,"enrollment":223,"conditions":270,"interventions":271},[90],[225],[74,227,197],{"trials":273,"activeCount":106},[],{"intervention":227,"totalTrials":144,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":290},{"trials":277,"activeCount":106},[],{"trials":279,"activeCount":106},[],{"trials":281,"activeCount":106},[],{"trials":283,"activeCount":106},[],{"trials":285,"activeCount":129,"soonestReadout":73},[286],{"nctId":71,"briefTitle":72,"status":118,"phases":287,"primaryCompletion":73,"completion":221,"start":222,"enrollment":223,"conditions":288,"interventions":289},[90],[225],[74,227,197],{"trials":291,"activeCount":106},[292],{"nctId":293,"briefTitle":294,"status":295,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT04286295","Cytisine Compared to Combination NRT in Relapsed Smokers","TERMINATED",[91],"2023-11-07","2022-03-14",13,[32,15],[227,302,303],"Nicoderm C-Q Transdermal Product","Nicorette Lozenge Product",{"intervention":79,"totalTrials":144,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":318,"NA":320},{"trials":307,"activeCount":106},[],{"trials":309,"activeCount":106},[],{"trials":311,"activeCount":106},[],{"trials":313,"activeCount":129,"soonestReadout":78},[314],{"nctId":76,"briefTitle":77,"status":118,"phases":315,"primaryCompletion":78,"completion":120,"start":121,"enrollment":122,"conditions":316,"interventions":317},[89],[124,125,126,127],[79,94],{"trials":319,"activeCount":106},[],{"trials":321,"activeCount":129,"soonestReadout":326},[322],{"nctId":323,"briefTitle":324,"status":118,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":332},"NCT07368062","Mental Health After Dexmedetomidine for Electrical Storm",[],"2027-12","2028-06","2025-03-15",70,[331],"Mental Health",[79],{"intervention":334,"totalTrials":335,"cells":336},"Clopidogrel",4,{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":374,"NA":385},{"trials":338,"activeCount":106},[],{"trials":340,"activeCount":106},[],{"trials":342,"activeCount":106},[],{"trials":344,"activeCount":129,"soonestReadout":68},[345,355,365],{"nctId":346,"briefTitle":347,"status":163,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":353},"NCT01894789","Ticagrelor vs Clopidogrel Effect on MFR in CAD Population",[88,89],"2015-03","2013-03",36,[15],[354,334],"Ticagrelor",{"nctId":356,"briefTitle":357,"status":163,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":364},"NCT00827346","Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty",[88,89],"2011-04","2009-01",100,[363],"Platelet Reactivity",[334,334,334,334],{"nctId":66,"briefTitle":67,"status":118,"phases":366,"primaryCompletion":68,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":373},[89],"2029-03","2021-06-28",135,[371,372],"Cardiac Allograft Vasculopathy","Heart Transplant",[69,334],{"trials":375,"activeCount":106},[376],{"nctId":377,"briefTitle":378,"status":163,"phases":379,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":384},"NCT02054663","Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?",[90],"2015-02","2013-12",60,[24],[334],{"trials":386,"activeCount":106},[],{"intervention":69,"totalTrials":144,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":412,"NA":414},{"trials":390,"activeCount":106},[],{"trials":392,"activeCount":106},[],{"trials":394,"activeCount":106},[],{"trials":396,"activeCount":129,"soonestReadout":68},[397,401],{"nctId":66,"briefTitle":67,"status":118,"phases":398,"primaryCompletion":68,"completion":367,"start":368,"enrollment":369,"conditions":399,"interventions":400},[89],[371,372],[69,334],{"nctId":402,"briefTitle":403,"status":295,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT02674958","Mobilization of Endothelial Progenitor Cells and Aspirin",[89],"2022-04-01","2016-05",6,[409],"Hypertrophic Obstructive Cardiomyopathy",[411],"Aspirin",{"trials":413,"activeCount":106},[],{"trials":415,"activeCount":106},[],{"intervention":42,"totalTrials":129,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":436,"NA":438},{"trials":419,"activeCount":106},[],{"trials":421,"activeCount":106},[],{"trials":423,"activeCount":106},[],{"trials":425,"activeCount":129,"soonestReadout":41},[426],{"nctId":39,"briefTitle":40,"status":118,"phases":427,"primaryCompletion":41,"completion":428,"start":429,"enrollment":361,"conditions":430,"interventions":434},[89],"2027-07","2026-02-13",[431,432,433],"Diabetes Mellitus, Type 2","Nicotine Addiction","Tobacco Dependence",[42,435],"Nicotine replacement",{"trials":437,"activeCount":106},[],{"trials":439,"activeCount":106},[],{"intervention":435,"totalTrials":129,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":454,"NA":456},{"trials":443,"activeCount":106},[],{"trials":445,"activeCount":106},[],{"trials":447,"activeCount":106},[],{"trials":449,"activeCount":129,"soonestReadout":41},[450],{"nctId":39,"briefTitle":40,"status":118,"phases":451,"primaryCompletion":41,"completion":428,"start":429,"enrollment":361,"conditions":452,"interventions":453},[89],[431,432,433],[42,435],{"trials":455,"activeCount":106},[],{"trials":457,"activeCount":106},[],{"intervention":459,"totalTrials":129,"cells":460},"Midodrine Oral",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":480,"NA":482},{"trials":462,"activeCount":106},[],{"trials":464,"activeCount":106},[],{"trials":466,"activeCount":106},[],{"trials":468,"activeCount":129,"soonestReadout":473},[469],{"nctId":470,"briefTitle":471,"status":246,"phases":472,"primaryCompletion":473,"completion":473,"start":249,"enrollment":474,"conditions":475,"interventions":479},"NCT06405555","Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension",[88,89],"2028-06-01",56,[476,477,478],"Heart Failure With Reduced Ejection Fraction","Hypotension","LV Dysfunction",[459],{"trials":481,"activeCount":106},[],{"trials":483,"activeCount":106},[],{"intervention":84,"totalTrials":129,"cells":485},{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":492,"PHASE4":501,"NA":503},{"trials":487,"activeCount":106},[],{"trials":489,"activeCount":106},[],{"trials":491,"activeCount":106},[],{"trials":493,"activeCount":129,"soonestReadout":83},[494],{"nctId":81,"briefTitle":82,"status":118,"phases":495,"primaryCompletion":83,"completion":326,"start":496,"enrollment":497,"conditions":498,"interventions":500},[89],"2025-01-20",256,[499,35],"ST Elevation Myocardial Infarction",[84],{"trials":502,"activeCount":106},[],{"trials":504,"activeCount":106},[],{"intervention":51,"totalTrials":129,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":524,"NA":526},{"trials":508,"activeCount":106},[],{"trials":510,"activeCount":106},[],{"trials":512,"activeCount":106},[],{"trials":514,"activeCount":129,"soonestReadout":46},[515],{"nctId":49,"briefTitle":50,"status":118,"phases":516,"primaryCompletion":46,"completion":46,"start":517,"enrollment":518,"conditions":519,"interventions":522},[89],"2019-01-15",194,[520,521],"Cardiac Sarcoidosis","Sarcoidosis",[51,523],"Methotrexate",{"trials":525,"activeCount":106},[],{"trials":527,"activeCount":106},[],{"intervention":523,"totalTrials":129,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":106},[],{"trials":533,"activeCount":106},[],{"trials":535,"activeCount":106},[],{"trials":537,"activeCount":129,"soonestReadout":46},[538],{"nctId":49,"briefTitle":50,"status":118,"phases":539,"primaryCompletion":46,"completion":46,"start":517,"enrollment":518,"conditions":540,"interventions":541},[89],[520,521],[51,523],{"trials":543,"activeCount":106},[],{"trials":545,"activeCount":106},[],{"intervention":60,"totalTrials":129,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":565,"NA":567},{"trials":549,"activeCount":106},[],{"trials":551,"activeCount":106},[],{"trials":553,"activeCount":106},[],{"trials":555,"activeCount":129,"soonestReadout":59},[556],{"nctId":57,"briefTitle":58,"status":118,"phases":557,"primaryCompletion":59,"completion":83,"start":558,"enrollment":559,"conditions":560,"interventions":564},[89],"2026-04-08",168,[561,562,563],"Inflammation","Community Acquired Pneumonia (CAP)","Inflammation Plaque, Atherosclerotic",[60],{"trials":566,"activeCount":106},[],{"trials":568,"activeCount":106},[],{"intervention":570,"totalTrials":129,"cells":571},"Dapagliflozin",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":592,"NA":594},{"trials":573,"activeCount":106},[],{"trials":575,"activeCount":106},[],{"trials":577,"activeCount":106},[],{"trials":579,"activeCount":129,"soonestReadout":584},[580],{"nctId":581,"briefTitle":582,"status":246,"phases":583,"primaryCompletion":584,"completion":585,"start":586,"enrollment":122,"conditions":587,"interventions":591},"NCT06907251","Dapagliflozin for Long COVID Syndrome",[89],"2028-06-30","2029-06-30","2026-04-01",[588,589,590],"COVID - 19","Long COVID Syndrome","SARS CoV-2",[570],{"trials":593,"activeCount":106},[],{"trials":595,"activeCount":106},[],{"intervention":55,"totalTrials":129,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":613,"NA":615},{"trials":599,"activeCount":106},[],{"trials":601,"activeCount":106},[],{"trials":603,"activeCount":106},[],{"trials":605,"activeCount":129,"soonestReadout":46},[606],{"nctId":53,"briefTitle":54,"status":118,"phases":607,"primaryCompletion":46,"completion":46,"start":608,"enrollment":609,"conditions":610,"interventions":612},[88,89],"2024-11-15",24,[611,15],"Diabetes Type 2",[55],{"trials":614,"activeCount":106},[],{"trials":616,"activeCount":106},[],{"intervention":64,"totalTrials":129,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":620,"activeCount":106},[],{"trials":622,"activeCount":106},[],{"trials":624,"activeCount":106},[],{"trials":626,"activeCount":106},[],{"trials":628,"activeCount":106},[],{"trials":630,"activeCount":129,"soonestReadout":59},[631],{"nctId":62,"briefTitle":63,"status":632,"phases":633,"primaryCompletion":59,"completion":59,"start":634,"enrollment":635,"conditions":636,"interventions":638},"ACTIVE_NOT_RECRUITING",[],"2022-07-01",48,[637],"Ischemic Heart Disease",[64],{"intervention":640,"totalTrials":95,"cells":641},"Rivaroxaban",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":672,"NA":685},{"trials":643,"activeCount":106},[],{"trials":645,"activeCount":106},[],{"trials":647,"activeCount":106},[],{"trials":649,"activeCount":106},[650,659],{"nctId":651,"briefTitle":652,"status":163,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT03331484","The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention",[89],"2023-07-06","2018-11-01",40,[18,24],[354,640],{"nctId":660,"briefTitle":661,"status":163,"phases":662,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":669},"NCT01675076","Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events",[89],"2017-10","2018-05","2013-01",663,[668],"Hematoma",[670,640,671],"Dabigatran","Apixaban",{"trials":673,"activeCount":106},[674],{"nctId":675,"briefTitle":676,"status":163,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":683},"NCT02168829","Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial",[90],"2025-08-14","2016-01",1284,[18,682],"Stroke",[640,684],"Acetylsalicylic acid",{"trials":686,"activeCount":106},[],{"intervention":688,"totalTrials":144,"cells":689},"Nicoderm Patch",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":720},{"trials":691,"activeCount":106},[],{"trials":693,"activeCount":106},[],{"trials":695,"activeCount":106},[],{"trials":697,"activeCount":106},[],{"trials":699,"activeCount":106},[700,708],{"nctId":701,"briefTitle":702,"status":295,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":335,"conditions":706,"interventions":707},"NCT02918500","Effect of Pre-op NRT on Peri-operative Complications and Long-term Abstinence: A Pilot Trial in Patients Undergoing CABG Surgery",[90],"2020-07-31","2017-10-23",[32],[688],{"nctId":709,"briefTitle":710,"status":163,"phases":711,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":717},"NCT01622998","Self-directed Titrated Transdermal Nicotine Patch Versus Standard Treatment for Smoking Cessation",[90],"2014-08","2014-09","2011-01",303,[32],[718,719],"NicoDerm Patch","Nicorette Inhaler",{"trials":721,"activeCount":106},[],{"intervention":723,"totalTrials":129,"cells":724},"Champix",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":733,"NA":747},{"trials":726,"activeCount":106},[],{"trials":728,"activeCount":106},[],{"trials":730,"activeCount":106},[],{"trials":732,"activeCount":106},[],{"trials":734,"activeCount":106},[735],{"nctId":736,"briefTitle":737,"status":163,"phases":738,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":742,"interventions":744},"NCT01623505","Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling",[90],"2014-06","2010-06",738,[32,743],"Psychiatric Illness",[723,745,746],"Transdermal Nicoderm patch combined with gum or inhaler","Transdermal Nicoderm patch",{"trials":748,"activeCount":106},[],{"intervention":745,"totalTrials":129,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":765},{"trials":752,"activeCount":106},[],{"trials":754,"activeCount":106},[],{"trials":756,"activeCount":106},[],{"trials":758,"activeCount":106},[],{"trials":760,"activeCount":106},[761],{"nctId":736,"briefTitle":737,"status":163,"phases":762,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":763,"interventions":764},[90],[32,743],[723,745,746],{"trials":766,"activeCount":106},[],{"intervention":746,"totalTrials":129,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":783},{"trials":770,"activeCount":106},[],{"trials":772,"activeCount":106},[],{"trials":774,"activeCount":106},[],{"trials":776,"activeCount":106},[],{"trials":778,"activeCount":106},[779],{"nctId":736,"briefTitle":737,"status":163,"phases":780,"primaryCompletion":739,"completion":739,"start":740,"enrollment":741,"conditions":781,"interventions":782},[90],[32,743],[723,745,746],{"trials":784,"activeCount":106},[],{"intervention":786,"totalTrials":129,"cells":787},"Vitamin D",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":807},{"trials":789,"activeCount":106},[],{"trials":791,"activeCount":106},[],{"trials":793,"activeCount":106},[],{"trials":795,"activeCount":106},[],{"trials":797,"activeCount":106},[798],{"nctId":799,"briefTitle":800,"status":163,"phases":801,"primaryCompletion":679,"completion":679,"start":665,"enrollment":802,"conditions":803,"interventions":806},"NCT01993537","The Role of Vitamin D in the Pathophysiology of Chronic Failure",[90],91,[804,805],"Vitamin D Deficiency","Chronic Heart Failure",[786],{"trials":808,"activeCount":106},[],{"intervention":218,"totalTrials":129,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":825},{"trials":812,"activeCount":106},[],{"trials":814,"activeCount":106},[],{"trials":816,"activeCount":106},[],{"trials":818,"activeCount":106},[],{"trials":820,"activeCount":106},[821],{"nctId":210,"briefTitle":211,"status":163,"phases":822,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":823,"interventions":824},[90],[29],[197,218],{"trials":826,"activeCount":106},[],{"intervention":828,"totalTrials":129,"cells":829},"Ticagrelor 60mg",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":853},{"trials":831,"activeCount":106},[],{"trials":833,"activeCount":106},[],{"trials":835,"activeCount":106},[],{"trials":837,"activeCount":106},[],{"trials":839,"activeCount":106},[840],{"nctId":841,"briefTitle":842,"status":295,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":36,"conditions":846,"interventions":850},"NCT03224923","A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)",[90],"2018-09-30","2017-08-18",[847,848,849,354],"Stable Coronary Syndrome","Percutaneous Coronary Intervention","Antiplatelet Therapy",[828,851,852],"Clopidogrel 75mg","Aspirin 81 mg",{"trials":854,"activeCount":106},[],{"intervention":851,"totalTrials":129,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":871},{"trials":858,"activeCount":106},[],{"trials":860,"activeCount":106},[],{"trials":862,"activeCount":106},[],{"trials":864,"activeCount":106},[],{"trials":866,"activeCount":106},[867],{"nctId":841,"briefTitle":842,"status":295,"phases":868,"primaryCompletion":844,"completion":844,"start":845,"enrollment":36,"conditions":869,"interventions":870},[90],[847,848,849,354],[828,851,852],{"trials":872,"activeCount":106},[],{"intervention":852,"totalTrials":129,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":883,"NA":889},{"trials":876,"activeCount":106},[],{"trials":878,"activeCount":106},[],{"trials":880,"activeCount":106},[],{"trials":882,"activeCount":106},[],{"trials":884,"activeCount":106},[885],{"nctId":841,"briefTitle":842,"status":295,"phases":886,"primaryCompletion":844,"completion":844,"start":845,"enrollment":36,"conditions":887,"interventions":888},[90],[847,848,849,354],[828,851,852],{"trials":890,"activeCount":106},[],{"intervention":892,"totalTrials":129,"cells":893},"Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":916},{"trials":895,"activeCount":106},[],{"trials":897,"activeCount":106},[],{"trials":899,"activeCount":106},[],{"trials":901,"activeCount":106},[],{"trials":903,"activeCount":106},[904],{"nctId":905,"briefTitle":906,"status":295,"phases":907,"primaryCompletion":908,"completion":909,"start":910,"enrollment":911,"conditions":912,"interventions":913},"NCT03729401","Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND",[90],"2024-03-31","2026-02-26","2019-08-22",39,[15,35],[892,914,915],"Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily","Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily",{"trials":917,"activeCount":106},[],{"intervention":914,"totalTrials":129,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":926,"PHASE4":928,"NA":934},{"trials":921,"activeCount":106},[],{"trials":923,"activeCount":106},[],{"trials":925,"activeCount":106},[],{"trials":927,"activeCount":106},[],{"trials":929,"activeCount":106},[930],{"nctId":905,"briefTitle":906,"status":295,"phases":931,"primaryCompletion":908,"completion":909,"start":910,"enrollment":911,"conditions":932,"interventions":933},[90],[15,35],[892,914,915],{"trials":935,"activeCount":106},[],{"intervention":915,"totalTrials":129,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":952},{"trials":939,"activeCount":106},[],{"trials":941,"activeCount":106},[],{"trials":943,"activeCount":106},[],{"trials":945,"activeCount":106},[],{"trials":947,"activeCount":106},[948],{"nctId":905,"briefTitle":906,"status":295,"phases":949,"primaryCompletion":908,"completion":909,"start":910,"enrollment":911,"conditions":950,"interventions":951},[90],[15,35],[892,914,915],{"trials":953,"activeCount":106},[],{"intervention":955,"totalTrials":129,"cells":956},"Spironolactone",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":965,"NA":982},{"trials":958,"activeCount":106},[],{"trials":960,"activeCount":106},[],{"trials":962,"activeCount":106},[],{"trials":964,"activeCount":106},[],{"trials":966,"activeCount":106},[967],{"nctId":968,"briefTitle":969,"status":163,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":22,"conditions":974,"interventions":981},"NCT03344159","Spironolactone Therapy in Chronic Stable Right HF Trial",[90],"2022-08-30","2024-05-01","2018-04-01",[975,976,977,978,979,980],"Chronic Right-Sided Heart Failure","Pulmonary Arterial Hypertension","Pulmonary Hypertension, Primary, 2","Pulmonary Hypertension, Primary, 3","Pulmonary Hypertension, Primary, 4","Cardiomyopathy Right Ventricular",[955],{"trials":983,"activeCount":106},[],{"intervention":985,"totalTrials":129,"cells":986},"low molecular weight heparin or unfractionated heparin",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":1006},{"trials":988,"activeCount":106},[],{"trials":990,"activeCount":106},[],{"trials":992,"activeCount":106},[],{"trials":994,"activeCount":106},[],{"trials":996,"activeCount":106},[997],{"nctId":998,"briefTitle":999,"status":295,"phases":1000,"primaryCompletion":350,"completion":350,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT00800137","Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial",[90],"2008-12",984,[668],[985,1005],"Warfarin or coumadin",{"trials":1007,"activeCount":106},[],{"intervention":1005,"totalTrials":129,"cells":1009},{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1018,"NA":1024},{"trials":1011,"activeCount":106},[],{"trials":1013,"activeCount":106},[],{"trials":1015,"activeCount":106},[],{"trials":1017,"activeCount":106},[],{"trials":1019,"activeCount":106},[1020],{"nctId":998,"briefTitle":999,"status":295,"phases":1021,"primaryCompletion":350,"completion":350,"start":1001,"enrollment":1002,"conditions":1022,"interventions":1023},[90],[668],[985,1005],{"trials":1025,"activeCount":106},[],{"intervention":1027,"totalTrials":129,"cells":1028},"Prednisone",{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1048},{"trials":1030,"activeCount":106},[],{"trials":1032,"activeCount":106},[],{"trials":1034,"activeCount":106},[],{"trials":1036,"activeCount":106},[],{"trials":1038,"activeCount":106},[1039],{"nctId":1040,"briefTitle":1041,"status":102,"phases":1042,"primaryCompletion":1043,"completion":1044,"start":1045,"enrollment":106,"conditions":1046,"interventions":1047},"NCT01210677","Cardiac Sarcoidosis Response To Steroids Trial",[90],"2016-04","2016-12","2014-04",[520,521],[1027],{"trials":1049,"activeCount":106},[],{"intervention":1051,"totalTrials":129,"cells":1052},"Cost-Free Pharmacotherapy Group",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1061,"NA":1072},{"trials":1054,"activeCount":106},[],{"trials":1056,"activeCount":106},[],{"trials":1058,"activeCount":106},[],{"trials":1060,"activeCount":106},[],{"trials":1062,"activeCount":106},[1063],{"nctId":1064,"briefTitle":1065,"status":163,"phases":1066,"primaryCompletion":1067,"completion":1067,"start":1068,"enrollment":518,"conditions":1069,"interventions":1071},"NCT00962988","Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease",[90],"2015-04","2009-12",[1070,32],"Cerebrovascular Disorders",[1051],{"trials":1073,"activeCount":106},[],{"intervention":1075,"totalTrials":129,"cells":1076},"Rosuvastatin",{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1085,"NA":1097},{"trials":1078,"activeCount":106},[],{"trials":1080,"activeCount":106},[],{"trials":1082,"activeCount":106},[],{"trials":1084,"activeCount":106},[],{"trials":1086,"activeCount":106},[1087],{"nctId":1088,"briefTitle":1089,"status":163,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":713,"enrollment":1092,"conditions":1093,"interventions":1096},"NCT02234492","The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients",[90],"2018-10",35,[1094,1095],"Human Immunodeficiency Virus (HIV)","Cardiovascular Disease (CVD)",[1075],{"trials":1098,"activeCount":106},[],{"intervention":719,"totalTrials":129,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1115},{"trials":1102,"activeCount":106},[],{"trials":1104,"activeCount":106},[],{"trials":1106,"activeCount":106},[],{"trials":1108,"activeCount":106},[],{"trials":1110,"activeCount":106},[1111],{"nctId":709,"briefTitle":710,"status":163,"phases":1112,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":1113,"interventions":1114},[90],[32],[718,719],{"trials":1116,"activeCount":106},[],{"intervention":1118,"totalTrials":129,"cells":1119},"Antiarrhythmic Drug Therapy",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1139},{"trials":1121,"activeCount":106},[],{"trials":1123,"activeCount":106},[],{"trials":1125,"activeCount":106},[],{"trials":1127,"activeCount":106},[],{"trials":1129,"activeCount":106},[1130],{"nctId":1131,"briefTitle":1132,"status":295,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":95,"conditions":1136,"interventions":1138},"NCT02114528","Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention",[90],"2015-11","2014-10",[124,1137],"Ventricular Arrhythmia",[1118],{"trials":1140,"activeCount":106},[],{"intervention":684,"totalTrials":129,"cells":1142},{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1151,"NA":1157},{"trials":1144,"activeCount":106},[],{"trials":1146,"activeCount":106},[],{"trials":1148,"activeCount":106},[],{"trials":1150,"activeCount":106},[],{"trials":1152,"activeCount":106},[1153],{"nctId":675,"briefTitle":676,"status":163,"phases":1154,"primaryCompletion":678,"completion":678,"start":679,"enrollment":680,"conditions":1155,"interventions":1156},[90],[18,682],[640,684],{"trials":1158,"activeCount":106},[],{"intervention":354,"totalTrials":144,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1177,"NA":1179},{"trials":1162,"activeCount":106},[],{"trials":1164,"activeCount":106},[],{"trials":1166,"activeCount":106},[],{"trials":1168,"activeCount":106},[1169,1173],{"nctId":346,"briefTitle":347,"status":163,"phases":1170,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1171,"interventions":1172},[88,89],[15],[354,334],{"nctId":651,"briefTitle":652,"status":163,"phases":1174,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":1175,"interventions":1176},[89],[18,24],[354,640],{"trials":1178,"activeCount":106},[],{"trials":1180,"activeCount":106},[],{"intervention":1182,"totalTrials":129,"cells":1183},"Adenosine",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1203,"NA":1205},{"trials":1185,"activeCount":106},[],{"trials":1187,"activeCount":106},[],{"trials":1189,"activeCount":106},[],{"trials":1191,"activeCount":106},[1192],{"nctId":1193,"briefTitle":1194,"status":295,"phases":1195,"primaryCompletion":1196,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1202},"NCT00612521","Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis",[89],"2008-08","2008-09","2007-08",200,[1201,15],"Coronary Artery Stenosis",[1182],{"trials":1204,"activeCount":106},[],{"trials":1206,"activeCount":106},[],{"intervention":1208,"totalTrials":129,"cells":1209},"Colchicine Oral Product",{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1216,"PHASE4":1229,"NA":1231},{"trials":1211,"activeCount":106},[],{"trials":1213,"activeCount":106},[],{"trials":1215,"activeCount":106},[],{"trials":1217,"activeCount":106},[1218],{"nctId":1219,"briefTitle":1220,"status":163,"phases":1221,"primaryCompletion":1222,"completion":1222,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1228},"NCT04181996","Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine",[89],"2025-12-16","2020-08-01",115,[27,1226,561,1227],"Atherosclerosis","Diabetes",[1208],{"trials":1230,"activeCount":106},[],{"trials":1232,"activeCount":106},[],{"intervention":1234,"totalTrials":129,"cells":1235},"Radioisotope",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1250,"NA":1252},{"trials":1237,"activeCount":106},[],{"trials":1239,"activeCount":106},[],{"trials":1241,"activeCount":106},[],{"trials":1243,"activeCount":106},[1244],{"nctId":1245,"briefTitle":1246,"status":163,"phases":1247,"primaryCompletion":1134,"completion":1134,"start":381,"enrollment":9,"conditions":1248,"interventions":1249},"NCT02043522","123I-mIBG SPECT Imaging",[89],[21,15],[1234],{"trials":1251,"activeCount":106},[],{"trials":1253,"activeCount":106},[],{"intervention":670,"totalTrials":129,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1268,"NA":1270},{"trials":1257,"activeCount":106},[],{"trials":1259,"activeCount":106},[],{"trials":1261,"activeCount":106},[],{"trials":1263,"activeCount":106},[1264],{"nctId":660,"briefTitle":661,"status":163,"phases":1265,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":1266,"interventions":1267},[89],[668],[670,640,671],{"trials":1269,"activeCount":106},[],{"trials":1271,"activeCount":106},[],{"intervention":671,"totalTrials":129,"cells":1273},{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1280,"PHASE4":1286,"NA":1288},{"trials":1275,"activeCount":106},[],{"trials":1277,"activeCount":106},[],{"trials":1279,"activeCount":106},[],{"trials":1281,"activeCount":106},[1282],{"nctId":660,"briefTitle":661,"status":163,"phases":1283,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":1284,"interventions":1285},[89],[668],[670,640,671],{"trials":1287,"activeCount":106},[],{"trials":1289,"activeCount":106},[],{"intervention":1291,"totalTrials":129,"cells":1292},"Angiotensin converting enzyme inhibitor",{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1299,"PHASE4":1312,"NA":1314},{"trials":1294,"activeCount":106},[],{"trials":1296,"activeCount":106},[],{"trials":1298,"activeCount":106},[],{"trials":1300,"activeCount":106},[1301],{"nctId":1302,"briefTitle":1303,"status":163,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT04591210","The COVID-RASi Trial (COVID-19)",[89],"2024-12-30","2021-01-27",372,[1309,27],"COVID-19",[1291,1311],"Angiotensin II Receptor Blockers",{"trials":1313,"activeCount":106},[],{"trials":1315,"activeCount":106},[],{"intervention":1311,"totalTrials":129,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1330,"NA":1332},{"trials":1319,"activeCount":106},[],{"trials":1321,"activeCount":106},[],{"trials":1323,"activeCount":106},[],{"trials":1325,"activeCount":106},[1326],{"nctId":1302,"briefTitle":1303,"status":163,"phases":1327,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1328,"interventions":1329},[89],[1309,27],[1291,1311],{"trials":1331,"activeCount":106},[],{"trials":1333,"activeCount":106},[],{"intervention":1335,"totalTrials":129,"cells":1336},"Eptifibatide facilitated PCI",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1353,"NA":1355},{"trials":1338,"activeCount":106},[],{"trials":1340,"activeCount":106},[],{"trials":1342,"activeCount":106},[],{"trials":1344,"activeCount":106},[1345],{"nctId":1346,"briefTitle":1347,"status":163,"phases":1348,"completion":1197,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1352},"NCT00251823","Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)",[89],"2005-07",400,[35],[1335],{"trials":1354,"activeCount":106},[],{"trials":1356,"activeCount":106},[],{"intervention":1358,"totalTrials":129,"cells":1359},"L-carnitine",{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1377,"NA":1379},{"trials":1361,"activeCount":106},[],{"trials":1363,"activeCount":106},[],{"trials":1365,"activeCount":106},[],{"trials":1367,"activeCount":106},[1368],{"nctId":1369,"briefTitle":1370,"status":295,"phases":1371,"primaryCompletion":1372,"completion":1373,"start":1374,"enrollment":351,"conditions":1375,"interventions":1376},"NCT00247975","Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy",[88,89],"2010-10","2011-10","2006-03",[21],[1358],{"trials":1378,"activeCount":106},[],{"trials":1380,"activeCount":106},[],{"intervention":1382,"totalTrials":129,"cells":1383},"Rivaroxaban 15 MG Oral Tablet [Xarelto]",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1402,"NA":1404},{"trials":1385,"activeCount":106},[],{"trials":1387,"activeCount":106},[],{"trials":1389,"activeCount":106},[],{"trials":1391,"activeCount":106},[1392],{"nctId":1393,"briefTitle":1394,"status":295,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1401},"NCT03630055","Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion",[89],"2025-06-26","2018-10-03",930,[1400],"Radial Artery Occlusion",[1382],{"trials":1403,"activeCount":106},[],{"trials":1405,"activeCount":106},[],{"intervention":1407,"totalTrials":129,"cells":1408},"Ticagrelor, Prasugrel, Clopidogrel",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1426,"NA":1428},{"trials":1410,"activeCount":106},[],{"trials":1412,"activeCount":106},[],{"trials":1414,"activeCount":106},[],{"trials":1416,"activeCount":106},[1417],{"nctId":1418,"briefTitle":1419,"status":163,"phases":1420,"primaryCompletion":1421,"completion":1422,"start":713,"enrollment":1423,"conditions":1424,"interventions":1425},"NCT02044146","A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk",[88,89],"2016-10","2017-06",120,[24,848],[1407],{"trials":1427,"activeCount":106},[],{"trials":1429,"activeCount":106},[],{"intervention":1431,"totalTrials":129,"cells":1432},"Colchicine 0.6 mg",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1449,"NA":1451},{"trials":1434,"activeCount":106},[],{"trials":1436,"activeCount":106},[],{"trials":1438,"activeCount":106},[],{"trials":1440,"activeCount":106},[1441],{"nctId":1442,"briefTitle":1443,"status":163,"phases":1444,"primaryCompletion":1445,"completion":496,"start":634,"enrollment":609,"conditions":1446,"interventions":1448},"NCT05253794","Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study",[88,89],"2024-07-31",[1447,561],"Aortic Stenosis",[1431],{"trials":1450,"activeCount":106},[],{"trials":1452,"activeCount":106},[],{"intervention":1454,"totalTrials":129,"cells":1455},"Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1473,"NA":1475},{"trials":1457,"activeCount":106},[],{"trials":1459,"activeCount":106},[],{"trials":1461,"activeCount":106},[],{"trials":1463,"activeCount":106},[1464],{"nctId":1465,"briefTitle":1466,"status":163,"phases":1467,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1199,"conditions":1470,"interventions":1472},"NCT01184300","ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation",[88,89],"2011-07","2010-08",[1471,24,848],"Stable Coronary Artery Disease",[1454],{"trials":1474,"activeCount":106},[],{"trials":1476,"activeCount":106},[],{"intervention":1478,"totalTrials":129,"cells":1479},"Point-of-Care Genetic Testing",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1499,"NA":1501},{"trials":1481,"activeCount":106},[],{"trials":1483,"activeCount":106},[],{"trials":1485,"activeCount":106},[],{"trials":1487,"activeCount":106},[1488],{"nctId":1489,"briefTitle":1490,"status":163,"phases":1491,"primaryCompletion":1492,"completion":350,"start":1493,"enrollment":1494,"conditions":1495,"interventions":1497},"NCT01452139","Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)",[88,89],"2012-09","2011-09",102,[1496],"STEMI",[1478,1498],"Prasugrel",{"trials":1500,"activeCount":106},[],{"trials":1502,"activeCount":106},[],{"intervention":1498,"totalTrials":129,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1517,"NA":1519},{"trials":1506,"activeCount":106},[],{"trials":1508,"activeCount":106},[],{"trials":1510,"activeCount":106},[],{"trials":1512,"activeCount":106},[1513],{"nctId":1489,"briefTitle":1490,"status":163,"phases":1514,"primaryCompletion":1492,"completion":350,"start":1493,"enrollment":1494,"conditions":1515,"interventions":1516},[88,89],[1496],[1478,1498],{"trials":1518,"activeCount":106},[],{"trials":1520,"activeCount":106},[],{"intervention":1522,"totalTrials":129,"cells":1523},"Clopidogrel 75 mg daily",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1541,"PHASE4":1543,"NA":1545},{"trials":1525,"activeCount":106},[],{"trials":1527,"activeCount":106},[],{"trials":1529,"activeCount":106},[1530],{"nctId":1531,"briefTitle":1532,"status":163,"phases":1533,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":1537,"conditions":1538,"interventions":1539},"NCT00228423","Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)",[88],"2009-06","2009-07","2006-05",113,[1226],[1522,1540],"water pill daily",{"trials":1542,"activeCount":106},[],{"trials":1544,"activeCount":106},[],{"trials":1546,"activeCount":106},[],{"intervention":1540,"totalTrials":129,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1550,"activeCount":106},[],{"trials":1552,"activeCount":106},[],{"trials":1554,"activeCount":106},[1555],{"nctId":1531,"briefTitle":1532,"status":163,"phases":1556,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":1537,"conditions":1557,"interventions":1558},[88],[1226],[1522,1540],{"trials":1560,"activeCount":106},[],{"trials":1562,"activeCount":106},[],{"trials":1564,"activeCount":106},[],{"intervention":1566,"totalTrials":129,"cells":1567},"intramyocardial VEGF angiogenesis",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1569,"activeCount":106},[],{"trials":1571,"activeCount":106},[],{"trials":1573,"activeCount":106},[1574],{"nctId":1575,"briefTitle":1576,"status":163,"phases":1577,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":11,"conditions":1581,"interventions":1582},"NCT00134433","Endothelial Modulation for Angiogenic Therapy",[87,88],"2007-03","2007-10","2004-11",[15],[1566,1583],"oral L-arginine supplementation",{"trials":1585,"activeCount":106},[],{"trials":1587,"activeCount":106},[],{"trials":1589,"activeCount":106},[],{"intervention":1583,"totalTrials":129,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1593,"activeCount":106},[],{"trials":1595,"activeCount":106},[],{"trials":1597,"activeCount":106},[1598],{"nctId":1575,"briefTitle":1576,"status":163,"phases":1599,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":11,"conditions":1600,"interventions":1601},[87,88],[15],[1566,1583],{"trials":1603,"activeCount":106},[],{"trials":1605,"activeCount":106},[],{"trials":1607,"activeCount":106},[],{"intervention":1609,"totalTrials":129,"cells":1610},"123I-CMICE-013",{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1623,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1612,"activeCount":106},[],{"trials":1614,"activeCount":106},[1615],{"nctId":1616,"briefTitle":1617,"status":163,"phases":1618,"primaryCompletion":1492,"completion":1492,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1622},"NCT01558362","A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers",[87],"2012-04",12,[15],[1609],{"trials":1624,"activeCount":106},[],{"trials":1626,"activeCount":106},[],{"trials":1628,"activeCount":106},[],{"trials":1630,"activeCount":106},[],{"intervention":1632,"totalTrials":129,"cells":1633},"Caffeine",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1635,"activeCount":106},[],{"trials":1637,"activeCount":106},[],{"trials":1639,"activeCount":106},[],{"trials":1641,"activeCount":106},[],{"trials":1643,"activeCount":106},[],{"trials":1645,"activeCount":106},[1646],{"nctId":1647,"briefTitle":1648,"status":163,"phases":1649,"primaryCompletion":1650,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1656},"NCT02095405","A Study of Caffeine on Cardiac Arrhythmias",[91],"2012-08","2015-08","2010-02",160,[1655,18],"Supraventricular Tachycardia (SVT)",[1632],{"intervention":302,"totalTrials":129,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1660,"activeCount":106},[],{"trials":1662,"activeCount":106},[],{"trials":1664,"activeCount":106},[],{"trials":1666,"activeCount":106},[],{"trials":1668,"activeCount":106},[],{"trials":1670,"activeCount":106},[1671],{"nctId":293,"briefTitle":294,"status":295,"phases":1672,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":1673,"interventions":1674},[91],[32,15],[227,302,303],{"intervention":303,"totalTrials":129,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1678,"activeCount":106},[],{"trials":1680,"activeCount":106},[],{"trials":1682,"activeCount":106},[],{"trials":1684,"activeCount":106},[],{"trials":1686,"activeCount":106},[],{"trials":1688,"activeCount":106},[1689],{"nctId":293,"briefTitle":294,"status":295,"phases":1690,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":1691,"interventions":1692},[91],[32,15],[227,302,303]]